<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/42/300cc–13" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/42/300cc–13/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/42/300cc–13/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_300cc_13"><akn:num>300cc–13</akn:num><akn:heading>Terry Beirn Community-Based AIDS Research Initiative</akn:heading><akn:content><akn:p>§ 300cc–13. Terry Beirn Community-Based AIDS Research Initiative(a) In generalAfter consultation with the Commissioner of Food and Drugs, the Director of the National Institutes of Health, acting through the Director of the National Institute of Allergy and Infectious Diseases, may make grants to public entities and nonprofit private entities concerned with acquired immune deficiency syndrome, and may enter into contracts with public and private such 11 So in original. entities, for the purpose of planning and conducting, in the community involved, clinical trials of experimental treatments for infection with the etiologic agent for such syndrome that are approved by the Commissioner of Food and Drugs for investigational use under regulations issued under section 355 of title 21.


(b) Requirement of certain projects(1) Financial assistance under subsection (a) shall include such assistance to community-based organizations and community health centers for the purpose of—(A) retaining appropriate medical supervision;

(B) assisting with administration, data collection and record management; and

(C) conducting training of community physicians, nurse practitioners, physicians’ assistants and other health professionals for the purpose of conducting clinical trials.


(2)(A) Financial assistance under subsection (a) shall include such assistance for demonstration projects designed to implement and conduct community-based clinical trials in order to provide access to the entire scope of communities affected by infections with the etiologic agent for acquired immune deficiency syndrome, including minorities, hemophiliacs and transfusion-exposed individuals, women, children, users of intravenous drugs, and individuals who are asymptomatic with respect to such infection.

(B) The Director of the National Institutes of Health may not provide financial assistance under this paragraph unless the application for such assistance is approved—(i) by the Commissioner of Food and Dr</akn:p></akn:content><akn:subsection eId="subsec_300cc_13_a"><akn:num>(a)</akn:num><akn:heading>In general</akn:heading><akn:content><akn:p>(a) In general After consultation with the Commissioner of Food and Drugs, the Director of the National Institutes of Health, acting through the Director of the National Institute of Allergy and Infectious Diseases, may make grants to public entities and nonprofit private entities concerned with acquired immune deficiency syndrome, and may enter into contracts with public and private such 11 So in original. entities, for the purpose of planning and conducting, in the community involved, clinical trials of experimental treatments for infection with the etiologic agent for such syndrome that are approved by the Commissioner of Food and Drugs for investigational use under regulations issued under section 355 of title 21.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_300cc_13_b"><akn:num>(b)</akn:num><akn:heading>Requirement of certain projects</akn:heading><akn:content><akn:p>(b) Requirement of certain projects</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_300cc_13_c"><akn:num>(c)</akn:num><akn:heading>Participation of private industry, schools of medicine and primary providers</akn:heading><akn:content><akn:p>(c) Participation of private industry, schools of medicine and primary providers Programs carried out with financial assistance provided under subsection (a) shall be designed to encourage private industry and schools of medicine, osteopathic medicine, and existing consortia of primary care providers organized to conduct clinical research concerning acquired immune deficiency syndrome to participate in, and to support, the clinical trials conducted pursuant to the programs.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_300cc_13_d"><akn:num>(d)</akn:num><akn:heading>Requirement of application</akn:heading><akn:content><akn:p>(d) Requirement of application The Secretary may not provide financial assistance under subsection (a) unless—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_300cc_13_e"><akn:num>(e)</akn:num><akn:heading>Authorization of appropriations</akn:heading><akn:content><akn:p>(e) Authorization of appropriations</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>